What were the main drivers of Gilead's revenue growth in Q2 2006?

Gilead's revenue growth was primarily driven by its HIV product portfolio, particularly the strong performance of Truvada, which saw a 143% increase in sales. Hepsera also contributed with a 24% increase. Additionally, royalty and contract revenue significantly increased, largely due to higher Tamiflu royalties from Roche.

How has Gilead's financial position changed regarding cash and debt?

Gilead's cash, cash equivalents, and marketable securities significantly increased to $3.30 billion by June 30, 2006, up 43% from December 31, 2005. This was largely due to proceeds from the issuance of $1.3 billion in convertible senior notes. The company also incurred interest expense related to a new $500 million senior credit facility entered into in December 2005.

What significant business developments or strategic moves did Gilead undertake during this period?

Gilead announced its agreement to acquire Raylo Chemicals for approximately $144.3 million and progressed with the acquisition of Corus Pharma. The company also launched Atripla, a single tablet regimen for HIV treatment, in July 2006 through its joint venture with Bristol-Myers Squibb. Furthermore, Gilead adopted SFAS 123R, a new accounting standard for stock-based compensation, which impacted its operating expenses.

What is the impact of the adoption of SFAS 123R on Gilead's financial results?

The adoption of SFAS 123R on January 1, 2006, requires Gilead to recognize the fair value of stock-based awards as an expense. This has resulted in increased stock-based compensation expense impacting cost of goods sold, R&D expenses, and SG&A expenses. For the first six months of 2006, total stock-based compensation expense recognized was $51.2 million.

GILD 10-Q Quarterly Report Q2 FY2006 — Revenue, Net Income, EPS

Summary

Gilead Sciences, Inc. demonstrated robust financial performance in the second quarter and first half of 2006, marked by significant revenue growth driven primarily by its HIV product portfolio. Total revenues increased by 32% year-over-year for the quarter and 36% for the half-year. This growth was largely propelled by Truvada, which saw a substantial 143% increase in sales for the quarter, and continued strong performance from Viread and Hepsera, despite a slight dip in Viread sales due to product mix shifts. The company also benefited from a notable increase in royalty and contract revenue, largely attributed to higher Tamiflu royalties from Roche. Gilead's financial health was further bolstered by a significant increase in cash, cash equivalents, and marketable securities, reaching $3.3 billion by June 30, 2006, aided by proceeds from the issuance of convertible senior notes. Strategic acquisitions and product development milestones, including the expected launch of Atripla and the pending acquisition of Raylo Chemicals, position Gilead for continued growth.

Key Highlights

1Total revenues grew by 32% to $685.3 million in Q2 2006 and by 36% to $1.38 billion in the first half of 2006, driven by strong product sales.
2HIV product sales increased by 38% to $475.4 million in Q2 2006, with Truvada sales soaring by 143% to $299.3 million.
3Royalty and contract revenue more than doubled in Q2 2006 to $94.6 million, primarily due to increased Tamiflu royalties from Roche.
4Cash, cash equivalents, and marketable securities increased by 43% to $3.30 billion by June 30, 2006.
5The company completed a significant financing round, issuing $1.3 billion in convertible senior notes and repurchased $544.9 million of its common stock.
6Gilead announced its intent to acquire Raylo Chemicals for approximately $144.3 million and also progressed with the planned acquisition of Corus Pharma.
7The company adopted SFAS 123R effective January 1, 2006, which requires expensing the fair value of stock-based awards, impacting operating expenses.

GILEAD SCIENCES, INC. Quarterly Report for Q2 Ended Jun 30, 2006

Summary

Key Highlights

Frequently Asked Questions